Company: RNAC
Filing Date: 2025-11-13
Form Type: 8-K
Source: 0001453687-25-000123
Chunk: 0

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-11-13
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure

Descartes-08 SLE Data and Myositis Indication

On November 13, 2025, Cartesian Therapeutics, Inc. (the “ Company”) issued a press release announcing initial data from its ongoing Phase 2 open-label trial of Descartes-08 in participants with systemic lupus erythematosus (“ SLE”) and its planned expansion of Descartes-08 into myositis. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Corporate Presentation

The Company from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. A copy of the Company’s corporate slide presentation highlighting the initial SLE data and the Company’s planned expansion of Descartes-08 into myositis is attached hereto as Exhibit 99.2 and incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events